Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco NASDAQ 100 ETF (QQQM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Invesco NASDAQ 100 ETFTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Invesco NASDAQ 100 ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Invesco NASDAQ 100 ETF trades at $289.69, while State Street SPDR S&P Biotech ETF trades at $152.12. Which is the better fit depends on your goals.

QQQMXBI
Sector
Broad Market / FactorBroad Market / Factor
52-Week High
$307.23$164.28
52-Week Low
$228.02$85.16

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco NASDAQ 100 ETF

QQQM trades at $286.58 with minimal daily movement (+0.09%) amid bearish technical signals. The ETF faces headwinds from stretched tech valuations and rising AI competition, though recent Nasdaq-100 additions like SpaceX provide diversification. Technical indicators show oversold conditions with RSI at 22.39, while moving averages signal continued downward pressure.

The outlook remains cautious due to valuation concerns and sector rotation risks. However, the lower 0.15% expense ratio versus QQQ offers cost efficiency for long-term growth exposure. Key risks include AI market saturation and tech sector volatility, balanced by the fund's concentrated exposure to leading U.S. innovation companies.

State Street SPDR S&P Biotech ETF

XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.

Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Invesco NASDAQ 100 ETF

QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.

Read more on QQQM

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI